Prospective evaluation of genomics-guided off-label treatment
K. Verkerk, A. C. Spiekman, S. F. Haj Mohammad, F. A. J. Verbeek, H. Timmer, M. A. van Maren, L. J. Zeverijn, B. S. Geurts, V. van der Noort, P. Roepman, A. M. L. Jansen, W. W. J. de Leng, H. Gelderblom, H. M. W. Verheul, E. E. Voest, H. M. W. Verheul, H. M. W. Verheul, E. E. Voest, H. H. Nienhuis, · 2026
Read Prospective evaluation of genomics-guided off-label treatment by K. Verkerk, A. C. Spiekman, S. F. Haj Mohammad, F. A. J. Verbeek, H. Timmer, M. A. van Maren, L. J. Zeverijn, B. S. Geurts, V. van der Noort, P. Roepman, A. M. L. Jansen, W. W. J. de Leng, H. Gelderblom, H. M. W. Verheul, E. E. Voest, H. M. W. Verheul, H. M. W. Verheul, E. E. Voest, H. H. Nienhuis, (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13171434.txt.
Description
A peer-reviewed research article from Europe PMC (2026). Anticancer drugs are frequently used off-label for tumours that are genetically similar to the approved indication. However, outcomes are rarely captured systematically, limiting evidence-based decision-making and risking repeated futile treatment. The Drug Rediscovery Protocol (DRUP; ClinicalTrials.gov ID: NCT02925234) prospectively evaluates such off-label use in patients in the Netherlands with advanced solid tumours who lack standard treatment options and harbour actionable genomic alterations1.
Catalog record
| CREATOR | K. Verkerk, A. C. Spiekman, S. F. Haj Mohammad, F. A. J. Verbeek, H. Timmer, M. A. van Maren, L. J. Zeverijn, B. S. Geurts, V. van der Noort, P. Roepman, A. M. L. Jansen, W. W. J. de Leng, H. Gelderblom, H. M. W. Verheul, E. E. Voest, H. M. W. Verheul, H. M. W. Verheul, E. E. Voest, H. H. Nienhuis, |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |